IP Verse

Compositions And Methods For Targeted Immunomodulatory Antibodies And Fusion Proteins - EP2542590

The patent EP2542590 was granted to The Johns Hopkins University on Apr 1, 2020. The application was originally filed on Mar 4, 2011 under application number EP11751481A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2542590

THE JOHNS HOPKINS UNIVERSITY
Application Number
EP11751481A
Filing Date
Mar 4, 2011
Status
Patent Maintained As Amended
Feb 28, 2020
Grant Date
Apr 1, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ARES TRADINGFeb 2, 2018WITHDRAWN

Patent Citations (20) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2005054832
DESCRIPTIONUS4244946
DESCRIPTIONUS4816567
DESCRIPTIONUS5631146
DESCRIPTIONUS5691145
DESCRIPTIONUS5736167
DESCRIPTIONUS5821337
DESCRIPTIONUS7060808
INTERNATIONAL-SEARCH-REPORTUS2006135459
INTERNATIONAL-SEARCH-REPORTUS2006263368
INTERNATIONAL-SEARCH-REPORTUS2007212337
INTERNATIONAL-SEARCH-REPORTUS2008075717
INTERNATIONAL-SEARCH-REPORTUS2009226435
OPPOSITIONUS2007244042
OPPOSITIONWO2009152610
OPPOSITIONWO2010003118
OPPOSITIONWO2011109789
OTHEREP2542590
OTHERUS2003125251
SEARCHUS2005054832

Non-Patent Literature (NPL) Citations (46) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Allignment of SEQ ID NO. 10 of D3 with SEQ ID NO. 87 of B1-
OPPOSITION- Allignment of SEQ ID NO. 744 of D2 with SEQ ID NO. 87 of B1-
OPPOSITION- COFFELT et al., "Angiopoietin 2 Stimulates TIE2-Expressing Monocytes To Suppress T Cell Activation and To Promote Regulatory T Cell Expansion", The Journal of Immunology, (2011), vol. 186, no. 7, pages 4183 - 4190-
OPPOSITION- FERNANDEZ-BOTRAN et al., "SOLUBLE CYTOKINE RECEPTORS IN BIOLOGICAL THERAPY", Expert Opinion on Biological Therapy, (2002), vol. 2, no. 6, pages 585 - 605-
OPPOSITION- FONSECA et al., "Capitalizing on the lmmunogenicity of Dying Tumor Cells", Clinical Cancer Research, (20080315), vol. 14, no. 6, pages 1603 - 1608-
OPPOSITION- JONES et al., "Degree of CD25 Expression in T-Cell Lymphoma Is Dependent onTissue Site: Implications for Targeted Therapy", Clinical Cancer Research, (2004), vol. 10, no. 16, pages 5587 - 5594-
OPPOSITION- JUNG et al., "Double Anti-angiogenic and Anti-inflammatory Protein Valpha Targeting VEGF-A and TNF-a in Retinopathy and Psoriasis", JBC, (20110223), vol. 286, no. 16, pages 14410 - 14418-
OPPOSITION- JUNG et al., "Double Anti-angiogenic and Anti-inflammatory Protein Valpha Targeting VEGF-A and TNF-a in Retinopathy and Psoriasis", JBC, (20110223), vol. 286, no. 16, pages 14410 - 14418, XP055462237-
OPPOSITION- KOH et al., "Double Antiangiogenic Protein, DAAP, Targeting VEGF-A and Angiopoietins in Tumor Angiogenesis, Metastasis, and Vascular Leakage", Cancer Cell, (20100817), vol. 18, no. 2, pages 171 - 184-
OPPOSITION- MALEK et al., "Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity", Immunity, (20100000), vol. 33, no. 2, pages 153 - 165, XP0055226773-
OPPOSITION- MALEK et al., "Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity", Immunity, (2010), vol. 33, no. 2, pages 153 - 165-
OPPOSITION- PODAR et al., "Inhibition of the TGF-P Signaling Pathway in Tumor Cells", Recent Results in Cancer Research, (20070000), vol. 172, pages 77 - 97, XP055462230-
OPPOSITION- PODAR et al., "Inhibition of the TGF-P Signaling Pathway in Tumor Cells", Recent Results in Cancer Research, (2007), vol. 172, pages 77 - 97-
OPPOSITION- REGNAULT et al., "Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization", J. Exp. Med., (1999), vol. 189, no. 2, pages 371 - 380-
OPPOSITION- SCHRAMA et al., "Antibody targeted drugs as cancer therapeutics", Nature Reviews Drug Discovery, (20060120), vol. 5, no. 2, pages 147 - 159-
OPPOSITION- Supplemental information published with D6-
OPPOSITION- TRAIL et al., "Monoclonal antibody drug conjugates in the treatment of cancer", Current Opinion in Immunology, (1999), vol. 11, no. 5, pages 584 - 588-
OPPOSITION- WANG et al., "Tumor necrosis factor and cancer, buddies or foes?", Acta Pharmacologica Sinica, (20080000), vol. 29, no. 11, pages 1275 - 1288, XP055462259-
OPPOSITION- WANG et al., "Tumor necrosis factor and cancer, buddies or foes?", Acta Pharmacologica Sinica, (2008), vol. 29, no. 11, pages 1275 - 1288-
OPPOSITION- YANG et al., "The Role of T reg Cells in the Cancer Immunological Response", American Journal of Immunology, (20090000), vol. 5, no. 1, pages 17 - 28, XP055462271-
OPPOSITION- YANG et al., "The Role of T reg Cells in the Cancer Immunological Response", American Journal of Immunology, (2009), vol. 5, no. 1, pages 17 - 28-
OPPOSITION- KOH et al., "Double Antiangiogenic Protein, DAAP, Targeting VEGF-A and Angiopoietins in Tumor Angiogenesis, Metastasis, and Vascular Leakage", Cancer Cell, (20100817), vol. 18, no. 2, pages 171 - 184, XP055462241
OPPOSITION- Young Jun Koh et al., "Supplemental Information Double Antiangiogenic Protein, DAAP, Targeting VEGF-A and Angiopoietins in Tumor Angiogenesis, Metastasis, and Vascular Leakage", Cancer Cell, (20100817), vol. 18, no. 2, pages 171 - 184, XP055462243
OPPOSITION- TRAIL et al., "Monoclonal antibody drug conjugates in the treatment of cancer", Current Opinion in Immunology, (19990000), vol. 11, no. 5, pages 584 - 588, XP004257589
OPPOSITION- SCHRAMA et al., "Antibody targeted drugs as cancer therapeutics", Nature Reviews Drug Discovery, (20060120), vol. 5, no. 2, pages 147 - 159, XP002566323
OPPOSITION- REGNAULT et al., "Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization", J. Exp. Med., (19990000), vol. 189, no. 2, pages 371 - 380, XP009073998
OPPOSITION- JONES et al., "Degree of CD25 Expression in T-Cell Lymphoma Is Dependent onTissue Site: Implications for Targeted Therapy", Clinical Cancer Research, (20040000), vol. 10, no. 16, pages 5587 - 5594, XP055462253
OPPOSITION- FONSECA et al., "Capitalizing on the lmmunogenicity of Dying Tumor Cells", Clinical Cancer Research, (20080315), vol. 14, no. 6, pages 1603 - 1608, XP055462274
OPPOSITION- FERNANDEZ-BOTRAN et al., "SOLUBLE CYTOKINE RECEPTORS IN BIOLOGICAL THERAPY", Expert Opinion on Biological Therapy, (20020000), vol. 2, no. 6, pages 585 - 605, XP009081996
OPPOSITION- COFFELT et al., "Angiopoietin 2 Stimulates TIE2-Expressing Monocytes To Suppress T Cell Activation and To Promote Regulatory T Cell Expansion", The Journal of Immunology, (20110000), vol. 186, no. 7, pages 4183 - 4190, XP055357255
OTHER- DUMONT; ARTEAGA, "Targeting the TGFP signaling network in human neoplasia", Cancer Cell, (20030000), vol. 3, pages 531 - 536, XP055493201-
OTHER- DUMONT; ARTEAGA, "Targeting the TGFβ signaling network in human neoplasia", Cancer Cell, (20030600), vol. 3, no. 6, pages 531 - 536, XP055492748-
OTHER- SCHMIDT S. R., "Fusion proteins as biopharmaceuticals - Applications and challenges", Current Opinion in Drug Discovery & Development, (20090300), vol. 12, no. 2, pages 1 - 12, XP009132026-
OTHER- SCHMIDT SR, "Fusion-proteins as biopharmaceuticals--applications and challenges", Current Opinion in Drug Discovery & Development, (20090301), vol. 12, no. 2, pages 1 - 12, XP009132026-
OTHER- Sheng Yao, Lieping Chen, "Contribution of B7-H1/PD-1 Co-inhibitory pathway to T-cell dysfunction in cancer", Sheng Yao, Lieping Chen, D.I. Gabrilovich and A.A. Hurwitz, Tumor-Induced Immune Suppression, (20080000), pages 29 - 40, XP055514882-
OTHER- Letourneau S; Krieg C; Pantaleo G; Boyman O, "IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets", Journal of Allergy and Clinical Immunology, (20090000), vol. 123, no. 4, pages 758 - 762, XP026445396
OTHER- GORELIK; FLAVELL, "Immune-mediated eradication of tumors through theblockade of transforming growth factor-beta signaling in T cells", Nature Medicine, (20011000), vol. 7, no. 10, pages 1118 - 1122, XP002298291
OTHER- GORELIK L; FLAVELL R A, "Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells", Nature Medicine, (20011001), vol. 7, no. 10, pages 1118 - 1122, XP002298291
OTHER- HOLASH et al., "VEGF-Trap: A VEGF blocker with potent antitumor effects", PNAS, (20020820), vol. 99, no. 17, pages 11393 - 11398, XP002300698
OTHER- HOLASH JOCELYN; ET AL, "VEGF-Trap: A VEGF blocker with potent antitumor effects", PNAS, (20020820), vol. 99, no. 17, pages 11393 - 11398, XP002300698
OTHER- MURAOKA R S; ET AL, "Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases", J. Clin. Invest., (20020601), vol. 109, no. 12, pages 1551 - 1559, XP002323808
OTHER- Rebecca S. Muraoka et al, "Blockade of TGF-beta inhibits mammary tumor cell viability,migration, and metastases", J. Clin. Invest, (20020600), vol. 109, no. 12, pages 1551 - 1559, XP002323808
OTHER- JING et al., "Depletion of CD4 T cells enhances inm1unotherapy for neuroblaston1a after syngeneic HSCT but compromises development of antitumor immune memory", Blood, (20090430), vol. 113, no. 18, pages 4449 - 4457, XP055492789
OTHER- JING W., et al., "Depletion of CD4 T cells enhances inm1unotherapy for neuroblaston1a after syngeneic HSCT but compromises development of antitumor immune memory", Blood, (20090430), vol. 113, no. 18, pages 4449 - 4457, XP055493212
OTHER- ORITZ-SANCHEZ E., et al., "Antibody-cytokine fusion proteins: applications in cancer therapy", Expert Opinion Biol. Ther., (20080000), vol. 8, no. 5, pages 609 - 632, XP002782442
OTHER- ORITZ-SANCHEZ et al., "Antibody-cytokine fusion proteins: applications in cancer therapy", Expert Opinion Biol. Ther., (20080500), vol. 8, no. 5, pages 609 - 632, XP008145785

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents